Aduhelm and How Money and Politics Supersede Science

What Was Aduhelm Supposed to Do?

Aduhelm was the brand name for aducanumab, a laboratory-made monoclonal antibody developed by Biogen and Eisai. It was designed to attach to aggregated beta-amyloid, a protein that accumulates in plaques in the brains of people with Alzheimer’s disease. The theory was straightforward: remove more amyloid, slow the disease.

Unfortunately, Alzheimer’s disease has never been famous for respecting straightforward theories. Amyloid is clearly associated with the disease, but lowering amyloid does not automatically guarantee a meaningful improvement in cognition. A clean brain scan is not much comfort if a person still cannot recognize a daughter, manage a checkbook, or find the bathroom at night.

Aduhelm was administered through an intravenous infusion approximately every four weeks. Treatment also required repeated MRI scans because the drug could cause amyloid-related imaging abnormalities, or ARIA, involving brain swelling and small areas of bleeding. FDA prescribing information required screening and follow-up imaging as part of treatment monitoring.

The Two Trials That Told Two Different Stories

EMERGE Offered Hope

Biogen conducted two large, similarly designed Phase 3 trials called EMERGE and ENGAGE. In EMERGE, also known as Study 302, the high-dose group appeared to experience about 22% less decline than the placebo group on the Clinical Dementia Rating–Sum of Boxes scale. Secondary measures also leaned in a favorable direction.

That result sounded promising, although the average difference was modest. It suggested slower worsening rather than recovery, and it was uncertain whether many families would notice the change in everyday life. Aduhelm was never shown to restore lost memory or reverse Alzheimer’s disease.

ENGAGE Refused to Cooperate

The problem was ENGAGE, or Study 301. It did not confirm the EMERGE result. The high-dose group failed to show the same benefit, even though the two trials had nearly identical designs. When two matching studies ask the same question and produce conflicting answers, science does not normally solve the disagreement by politely ignoring the inconvenient one.

Both trials had originally been stopped in March 2019 after a planned futility analysis concluded that they were unlikely to succeed. Later, Biogen reviewed a larger dataset that included additional observations collected before the shutdown and argued that EMERGE had become positive. FDA reviewers acknowledged that the later dataset made EMERGE look stronger, but the negative ENGAGE trial remained an unresolved scientific problem.

The Pooled Evidence Was Hardly a Victory Parade

A JAMA Internal Medicine patient summary concluded that when both trials were considered together, Aduhelm did not show an overall improvement in memory, reasoning, learning, or daily functioning compared with placebo. One study suggested a small slowing of decline; the other did not. That is less “medical moon landing” and more “the rocket left the launchpad, made a worrying noise, and landed in a neighboring parking lot.”

The FDA Advisory Committee Said No

In November 2020, the FDA asked an independent advisory committee to evaluate the evidence. On the central question of whether EMERGE could provide primary evidence of effectiveness when considered with ENGAGE and the earlier trial data, the vote was zero yes, ten no, and one uncertain.

Not a single committee member voted yes. That did not legally bind the FDA, but advisory committees exist to provide independent scientific judgment, especially when an application is controversial. Approving the drug after such a vote made the committee appear less like an expert safeguard and more like an elaborate suggestion box placed beside a locked door.

Three advisory committee members later resigned following the approval. Their concern was not simply that the FDA had reached a different conclusion. The deeper concern was that the agency had changed the question. Instead of approving Aduhelm through the traditional pathway based on demonstrated clinical benefit, the FDA used accelerated approval based on amyloid reduction as a surrogate endpoint.

Accelerated Approval: A Useful Tool Used in a Risky Way

The accelerated approval pathway was created to give patients with serious diseases earlier access to promising treatments. It permits the FDA to approve a drug based on a surrogate endpoint considered reasonably likely to predict clinical benefit. The company must then complete a confirmatory trial showing that patients actually benefit.

This mechanism has saved lives, particularly in areas such as HIV and cancer. The problem is not accelerated approval itself. The problem arises when the surrogate marker is uncertain, the clinical evidence is contradictory, and the confirmatory trial may take years to arrive.

In Aduhelm’s case, the FDA spent months reviewing the application under the traditional approval framework before pivoting to accelerated approval. A congressional investigation later reported that the switch occurred during an abbreviated review lasting roughly three weeks. The agency approved Aduhelm because it substantially reduced amyloid plaques, even though the link between that reduction and a clinically meaningful benefit remained disputed.

A 2025 report from the Department of Health and Human Services Office of Inspector General examined 24 accelerated approvals and identified concerns in three, including aducanumab. The report found instances in which the FDA relied on analyses outside sponsors’ original plans, approved drugs despite objections from reviewers or advisory committees, and failed to maintain complete documentation of certain sponsor meetings. The OIG recommended stronger guardrails and better records.

When Regulatory Collaboration Becomes Too Cozy

Drug developers and regulators must communicate. Clinical trials are expensive, technically complex, and ethically sensitive. Sponsors need guidance about endpoints, patient selection, safety monitoring, and statistical design. Communication itself is not evidence of corruption.

The Aduhelm investigation nevertheless found an unusually close pattern of interaction. Congressional investigators identified 66 calls and substantive email exchanges that were not formally documented. They also concluded that FDA and Biogen staff worked together on a joint briefing document for the advisory committee, giving the company insight into the agency’s positions while major disagreements remained within the FDA itself.

This matters because public trust depends not only on whether regulators believe they behaved properly, but also on whether the process can be independently reconstructed. When records are missing and the sponsor appears to be sitting unusually close to the referee, people naturally begin checking whether both teams are using the same locker room.

The available investigations do not prove that elected officials ordered the FDA to approve Aduhelm or that money was exchanged for a favorable ruling. The more defensible conclusion is that institutional urgency, sponsor influence, commercial incentives, patient advocacy, and political demand for an Alzheimer’s breakthrough created an environment in which scientific uncertainty was treated as a hurdle to manage rather than a reason to wait.

The $56,000 Question

Biogen initially priced Aduhelm at approximately $56,000 per patient per year, excluding the costs of diagnostic testing, infusions, MRI monitoring, physician visits, and treatment of complications. The company later cut the list price in half to $28,200, but the original number had already become a symbol of pharmaceutical audacity.

Congressional investigators reported that internal Biogen documents projected potential peak revenue of as much as $18 billion annually. One company presentation described an ambition to “make history,” while pricing consultants indicated that a price above $40,000 could maximize revenue. Biogen also estimated that Aduhelm might cost Medicare $12 billion in a single year under certain adoption assumptions.

Those figures transformed a scientific disagreement into a national budget problem. Most people eligible for an Alzheimer’s treatment are older adults, making Medicare the obvious payer. Medicare Part B generally covers physician-administered infusion drugs, with beneficiaries commonly responsible for 20% coinsurance unless they have supplemental coverage. At the original price, the patient’s share could be financially punishing even before the supporting medical services were added.

High prices do not automatically make a drug bad, just as cheap prices do not make one effective. A transformative treatment can justify substantial spending. Aduhelm’s problem was the combination of extraordinary cost and uncertain clinical value. It asked the public to pay blockbuster money for evidence that looked more like a trailer than the full movie.

Medicare Became the Second Regulator

FDA approval determines whether a drug may be marketed. It does not guarantee that Medicare must cover it without restrictions. The Centers for Medicare & Medicaid Services conducted its own review, considering more than 10,000 public comments and over 250 peer-reviewed documents.

In April 2022, CMS limited coverage of accelerated-approved anti-amyloid antibodies such as Aduhelm to patients participating in qualifying FDA- or NIH-approved clinical trials. The agency said traditionally approved drugs in the same class could receive broader coverage through evidence-development registries. CMS emphasized that its decision was based on whether treatment was reasonable and necessary, not on the price alone.

Supporters accused Medicare of blocking access to an FDA-approved therapy. Critics argued that CMS had done what the FDA had not: connected taxpayer-funded coverage to proof of patient benefit. The episode exposed an awkward regulatory split. One federal agency said amyloid reduction was enough for market access, while another effectively replied, “Interesting. Please bring clinical outcomes.”

Politics entered from every direction. Patient groups pressed for access. Fiscal watchdogs worried about Medicare spending. Members of Congress investigated the FDA and Biogen. Drug companies warned that restricted coverage could chill innovation. Each position contained a legitimate concern, which is exactly why strong scientific standards were so important. Evidence should have been the common referee, not merely one player arguing from the sidelines.

Safety Was Not a Minor Footnote

Aduhelm’s uncertain benefit had to be weighed against a clearly measurable risk. In the clinical trials, approximately 41% of patients receiving high-dose treatment experienced ARIA involving brain swelling, bleeding, or both. Many cases produced no symptoms and resolved with monitoring or interrupted dosing, but some patients developed headaches, dizziness, confusion, nausea, or visual changes. A small percentage required hospitalization or experienced lasting impairment.

This made the benefit-risk calculation especially uncomfortable. A patient was being asked to accept monthly infusions, repeated brain scans, a substantial chance of an imaging abnormality, and potentially large out-of-pocket costs for a treatment whose practical effect might not be noticeable.

For families confronting Alzheimer’s disease, however, even a slim possibility of slowing decline can feel priceless. That emotional reality should be respected, not exploited. Desperation is not informed consent, and hope should never be used as a substitute for a statistically and clinically persuasive result.

What Happened to Aduhelm?

Commercial adoption remained extremely limited. Several major medical centers declined to offer the treatment, physicians remained skeptical, and Medicare’s coverage restriction sharply reduced the potential patient population. Aduhelm never became the blockbuster imagined in early corporate forecasts.

In January 2024, Biogen announced that it would discontinue Aduhelm’s development and commercialization and terminate ENVISION, the confirmatory study required for accelerated approval. The company said the decision was a matter of resource allocation rather than a newly identified safety or efficacy concern. Aduhelm’s commercial availability ended in November 2024, and the accelerated approval indication was formally listed as withdrawn.

The confirmatory trial therefore did not deliver the definitive answer that accelerated approval was supposed to produce. The product disappeared, while the scientific question surrounding its clinical value remained incompletely resolved.

That does not mean the entire anti-amyloid strategy failed. Lecanemab later obtained traditional FDA approval after a confirmatory trial demonstrated a modest slowing of clinical decline, and donanemab was approved on clinical evidence in early Alzheimer’s disease. These drugs carry their own costs, risks, and debates, but their development illustrates the proper lesson: a biological effect becomes medically meaningful only when rigorous trials show that it helps patients.

Did Money and Politics Really Supersede Science?

The answer requires precision. There is no public proof that Aduhelm was approved through a simple political command or an illegal financial transaction. Saying otherwise would turn legitimate criticism into conspiracy theater, a genre already supplied with more than enough enthusiastic performers.

There is, however, substantial evidence that commercial and institutional incentives moved faster than the science:

• The pivotal trials produced contradictory clinical results.
• The FDA’s independent advisory committee overwhelmingly rejected the main effectiveness argument.
• The approval standard shifted late in the review from clinical benefit to amyloid reduction.
• Some FDA-Biogen interactions were unusually close or inadequately documented.
• The initial label was broader than the population studied.
• Biogen set a blockbuster price while acknowledging major costs to Medicare and patients.
• The required confirmatory program ended without verifying benefit.

Together, these facts support a serious conclusion: Aduhelm’s approval process allowed hope, urgency, revenue expectations, institutional reputation, and political pressure to outrun scientific certainty. Science was not absent, but it was placed in the back seat and repeatedly asked not to complain about the driving.

The Aduhelm Experience: What People Lived Through

For Patients and Families, the Headlines Created Emotional Whiplash

Imagine caring for a spouse whose memory is slowly disappearing. A headline announces the first new Alzheimer’s treatment in nearly two decades. The word “approval” sounds final and authoritative. Families may reasonably assume that the drug has been proven to work, because that is what approval usually means in everyday language.

Then come the qualifications. The drug removes plaque, but its effect on memory is uncertain. One trial was positive; another was negative. Treatment requires monthly infusions and repeated MRI scans. Brain swelling and bleeding are common imaging findings. Medicare coverage may be unavailable outside a trial. The annual price is more than many households earn.

The experience was not simple hope or simple disappointment. It was hope delivered with an instruction manual, a liability waiver, a financing discussion, and a statistical argument nobody expected to study after dinner.

For Clinicians, Approval Did Not End the Scientific Debate

Doctors were placed in an uncomfortable position. Some patients arrived asking for an approved breakthrough. Clinicians then had to explain that regulatory authorization did not equal proof of noticeable benefit. They also had to discuss eligibility testing, infusion logistics, MRI capacity, ARIA management, anticoagulant use, caregiver expectations, and financial exposure.

Many respected medical centers chose not to administer Aduhelm. That decision carried its own emotional cost. Saying no to an approved drug can sound paternalistic, especially to families willing to accept almost any risk. Yet prescribing a treatment with unclear benefit can also violate the clinician’s obligation to avoid harm.

For Researchers, the Case Damaged the Meaning of Endpoints

The Aduhelm experience sharpened an old lesson: surrogate markers are useful servants but dangerous bosses. Researchers need biomarkers because waiting years for clinical outcomes can make drug development painfully slow. Yet a biomarker must reliably predict something patients value.

Amyloid reduction is biologically interesting. It may be part of an effective treatment strategy. But treating a scan as though it were equivalent to preserving cognition risks confusing disease pathology with patient benefit. Aduhelm demonstrated why clinical outcomes cannot be treated as decorative accessories added after approval.

For Taxpayers, One Company’s Price Became Everyone’s Problem

The cost debate showed how a pharmaceutical company’s pricing decision can ripple through a public insurance system. Medicare could not treat a $56,000 infusion drug as a private transaction between Biogen and individual patients. Potential spending affected premiums, federal budgets, supplemental insurers, and taxpayers who would never use Aduhelm.

That collective financial exposure made political intervention inevitable. Once public money is involved, demands for evidence are not hostility to innovation. They are basic stewardship.

For Regulators, Trust Became the Most Expensive Casualty

The lasting experience of Aduhelm may be less about one drug than about confidence in the FDA. Regulatory agencies depend on public belief that standards are stable, decisions are transparent, and scientific disagreements are handled openly.

When an advisory committee votes almost unanimously against an application, the agency changes pathways late in the process, interactions with the sponsor are incompletely documented, and the confirmatory trial is eventually abandoned, skepticism is not irrational. Trust is not restored by insisting that the public misunderstood. It is restored by designing a process that is harder to misunderstand.

Conclusion: Hope Needs Evidence, Not a Marketing Budget

Aduhelm was neither a meaningless molecule nor the revolution promised at launch. It removed amyloid and helped reopen serious investment in disease-modifying Alzheimer’s therapies. But the approval also demonstrated what can happen when a desperate medical need collides with conflicting data, flexible regulation, corporate ambition, and political pressure.

The central lesson is not that regulators should never take risks. Patients with fatal and disabling diseases cannot wait for perfect certainty. The lesson is that uncertainty must be honestly priced, clearly labeled, tightly monitored, and resolved through rapid confirmatory trials. When the evidence is weak, the marketing should not be strong enough to drown it out.